Study of the metabolomic relationship between lung cancer and chronic obstructive pulmonary disease based on direct infusion mass spectrometry

被引:19
作者
Callejon-Leblic, B. [1 ]
Pereira-Vega, A. [2 ]
Vazquez-Gandullo, E. [2 ]
Sanchez-Ramos, J. L. [3 ]
Gomez-Ariza, J. L. [1 ]
Garcia-Barrera, T. [1 ]
机构
[1] Univ Huelva, Fac Expt Sci, Res Ctr Hlth & Environm RENSMA, Dept Chem, Campus El Carmen, Huelva 21007, Spain
[2] Juan Ramon Jimenez Hosp, Pneumonol Area, Huelva, Spain
[3] Univ Huelva, Nursing Dept, Huelva, Spain
关键词
Metabolomic fingerprinting; Lung cancer; Chronic obstructive pulmonary disease; Serum; Direct infusion; Mass spectrometry; SERUM; BIOMARKERS; DISCRIMINATION; PROGRESSION; PROFILES; MARKERS; PLASMA; URINE;
D O I
10.1016/j.biochi.2018.11.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The high prevalence of lung cancer (LC) has triggered the search of biomarkers for early diagnosis of this disease. For this purpose the study of metabolic changes related to the development of lung cancer could provide interesting information about its early diagnosis. In this sense, chronic obstructive pulmonary disease (COPD), a disease associated with tumor development, is a comorbidity that increases the risk of onset and progression of lung neoplasia and has also to be considered in the study of pathology related to lung cancer. This work develop a metabolomic approach based on direct infusion mass spectrometry using a hybrid triple quadrupole-time of flight mass spectrometer (DI-ESI-QqQ-TOF-MS) in order to identify altered metabolites from serum of LC and COPD patients and evaluate its relationship and implication in the progression of LC. This methodology has been applied to 30 serum samples from LC, 30 healthy patients used as controls (HC) and 30 serum samples from COPD to found altered metabolites from both LC and COPD diseases. In addition, some metabolic differences and similarities were found in Pulmonary Emphysema and Chronic Bronchitis patients. On the other hand, altered metabolites were studied in different stages of LC (II, III and IV) to evaluate the perturbation of them throughout the progression of disease. The sample treatment consisted of the extraction of polar and non-polar metabolites from serum that was later infused into the mass spectrometer using an electrospray ionization source in positive and negative mode. Partial least squares discriminant analysis (PLS-DA) allowed a classification between LC, HC and COPD groups in all acquisition modes. A total of 35 altered and common metabolites between LC and COPD, including amino acids, fatty acids, lysophospholipids, phospholipids and triacylglycerides were identified, being alanine, aspartate and glutamate metabolism the most altered. Finally, ROC curves were applied to the dataset and metabolites with ADC value higher than 0.70 were considered as relevant in the progression of LC. (C) 2018 Published by Elsevier B.V.
引用
收藏
页码:111 / 122
页数:12
相关论文
共 50 条
  • [41] Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform
    Callejon-Leblic, Belen
    Garcia-Barrera, Tamara
    Gravalos-Guzman, Jesus
    Pereira-Vega, Antonio
    Luis Gomez-Ariza, Jose
    JOURNAL OF PROTEOMICS, 2016, 145 : 197 - 206
  • [42] Lung cancer screening in patients with chronic obstructive pulmonary disease
    Gonzalez, Jessica
    Marin, Marta
    Sanchez-Salcedo, Pablo
    Zulueta, Javier J.
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (08)
  • [43] Chronic obstructive pulmonary disease (COPD) and lung cancer screening
    Young, Robert P.
    Hopkins, Raewyn J.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (03) : 347 - 360
  • [44] Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer
    López-Encuentra, A
    Astudillo, J
    Cerezal, J
    Gonzalez-Aragoneses, F
    Novoa, N
    Sánchez-Palencia, A
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2005, 27 (01) : 8 - 13
  • [45] RELATIONSHIP BETWEEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CORONARY ATHEROSCLEROTIC
    Zhang, H.
    Wang, Z.
    RESPIROLOGY, 2011, 16 : 115 - 115
  • [46] Systemic inflammation in chronic obstructive pulmonary disease and lung cancer: common driver of pulmonary cachexia?
    Ceelen, Judith J. M.
    Langen, Ramon C. J.
    Schols, Annemie M. W. J.
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2014, 8 (04) : 339 - 345
  • [47] Prevalence of undiagnosed and undertreated chronic obstructive pulmonary disease in lung cancer population
    Zhang, Jing
    Zhou, Jie-bai
    Lin, Xin-feng
    Wang, Qun
    Bai, Chun-xue
    Hong, Qun-ying
    RESPIROLOGY, 2013, 18 (02) : 297 - 302
  • [48] Unpredictable episodic breathlessness in patients with advanced chronic obstructive pulmonary disease and lung cancer: a qualitative study
    Linde, P.
    Hanke, G.
    Voltz, R.
    Simon, S. T.
    SUPPORTIVE CARE IN CANCER, 2018, 26 (04) : 1097 - 1104
  • [49] Hospitalizations at the End of Life Among Chronic Obstructive Pulmonary Disease and Lung Cancer Patients: A Nationwide Study
    Costa, Ana Rute
    Lunet, Nuno
    Martins-Branco, Diogo
    Gomes, Barbara
    Lopes, Silvia
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2021, 62 (01) : 48 - 57
  • [50] CT-Based Radiomic Nomogram for the Prediction of Chronic Obstructive Pulmonary Disease in Patients with Lung cancer
    Zhou, Taohu
    Tu, Wenting
    Dong, Peng
    Duan, Shaofeng
    Zhou, Xiuxiu
    Ma, Yanqing
    Wang, Yun
    Liu, Tian
    Zhang, Hanxiao
    Feng, Yan
    Huang, Wenjun
    Ge, Yanming
    Liu, Shiyuan
    Li, Zhaobin
    Fan, Li
    ACADEMIC RADIOLOGY, 2023, 30 (12) : 2894 - 2903